Stay Informed
of New Reports
Twitter
Where To Report Waste
Fraud, Abuse, Or Retaliation
Where To Report Waste Fraud, Abuse, Or Retaliation

Medicare Part D and Beneficiaries Could Realize Significant Spending Reductions With Increased Biosimilar Use

Submitting OIG: 
Department of Health & Human Services OIG
Date Issued: 
Tuesday, March 29, 2022
Agency Reviewed / Investigated: 
Department of Health & Human Services
Submitting OIG-Specific Report Number: 
OEI-05-20-00480
Component, if applicable: 
Centers for Medicare & Medicaid Services
Centers for Medicare and Medicaid Services
Location(s): 
United States
Type of Report: 
Inspection / Evaluation
Questioned Costs: 
$0
Funds for Better Use: 
$0
Number of Recommendations: 
2
View Document: 
AttachmentSize
PDF icon OEI-05-20-00480.pdf1.19 MB

Related Open Recommendations

Recommendation Number Recommendation Status Significant Recommendation Additional Details
22-E-05-014.01 Open No
CMS should Encourage Part D plans to increase access to and use of biosimilars.
22-E-05-014.02 Open No
CMS should Monitor Part D plans’ submitted formularies to determine whether they discourage beneficiaries from using biosimilars
Displaying 2 of 2 Recommendations